Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy

Corporate Breaking News

Home : Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy

Dec 24 2021	Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy
SAN FRANCISCO and SUZHOU, China, Dec. 24, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other...


Source:https://www.prnewswire.com:443/news-releases/innovent-announces-nmpa-of-china-acceptance-of-a-supplemental-new-drug-application-for-tyvyt-sintilimab-injection-plus-bevacizumab-biosimilar-injection-and-chemotherapy-in-patients-with-egfr-mutated-non-squamou

Related News
» Instant Noodles Market to grow by USD 5.06 billion from 2020 to 2025 \| Growing Demand for Convenient Food Products to Boost Market Growth \| 17000+ Technavio Reports » Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase